Doyle Thomas James's Form 4 filing
Kura Oncology, Inc. (KURA) · filed Jan 27, 2026
- Accession no.
- 0001193125-26-025302
- Filed
- Jan 27, 2026
- Trade date
- Jan 27, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $60.4K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Doyle Thomas JamesCIK 0001910331 | Officer (SVP, Finance & Accounting) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Common Stock | SSaleDisposed | −2,226 | $8.46 | −$18,831.96 | 150,083 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −1,114 | $8.46 | −$9,424.44 | 148,969 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −695 | $8.46 | −$5,879.7 | 148,274 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −2,226 | $8.46 | −$18,831.96 | 146,048 | Direct | |
| Jan 27, 2026 | Common Stock | SSaleDisposed | −881 | $8.46 | −$7,453.26 | 145,167 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.